Cerevast Therapeutics

Cerevast Therapeutics, Inc. is a medical technology company with primary emphasis in the field of SonoLysis for the treatment acute ischemic stroke and other vascular disorders. This non-invasive treatment is administered with Cerevast’s proprietary ultrasonic headframe called the ClotBust-ERTM, an operator independent device that can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast was formed in September of 2009 following the acquisition of substantially all of the assets of ImaRx Therapeutics, Inc. – a publicly traded company focused on the development of microsphere contrast agents and therapeutics. Through this acquisition, Cerevast gained title to the dominant intellectual property estate and an extensive data package of pre-clinical and clinical studies.

Cerevast has assembled a management team with extensive technical, scientific, commercial and regulatory expertise. The company has also assembled a Scientific Advisory Board comprised of globally recognized clinicians, all of whom are leading experts in the field of SonoLysis, ultrasound development and stroke treatment.

The company’s headquarters are located in Redmond, Washington.

Company Growth (employees)
Redmond, US
Size (employees)
11 (est)
Cerevast Therapeutics was founded in 2015 and is headquartered in Redmond, US

Cerevast Therapeutics Office Locations

Cerevast Therapeutics has an office in Redmond
Redmond, US (HQ)
100 11601 Willows Rd

Cerevast Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$22.4 m

Latest funding size

$11.4 m

Time since last funding

almost 3 years


Cerevast Therapeutics's latest funding round in March 2015 was reported to be $11.4 m. In total, Cerevast Therapeutics has raised $22.4 m

Cerevast Therapeutics's Web-traffic and Trends

Cerevast Therapeutics Online and Social Media Presence

Cerevast Therapeutics Company Life and Culture

You may also be interested in